Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 21

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 

AbbVie Inc. and Subsidiaries

Condensed Consolidated Statements of Earnings (unaudited)

Three months endedJune 30,Six months endedJune 30,(in millions, except per share data)2025202420252024Net revenues$15,423 $14,462 $28,766 $26,772 Cost of products sold4,346 4,202 8,348 8,296 Selling, general and administrative3,253 3,377 6,546 6,692 Research and development2,131 1,948 4,198 3,887 Acquired IPR&D and milestones823 937 1,071 1,101 Other operating income(24)— (24)— Total operating costs and expenses10,529 10,464 20,139 19,976 Operating earnings4,894 3,998 8,627 6,796 Interest expense, net678 506 1,305 959 Net foreign exchange loss23 1 27 5 Other expense, net2,639 1,345 4,080 1,931 Earnings before income tax expense1,554 2,146 3,215 3,901 Income tax expense613 773 985 1,156 Net earnings941 1,373 2,230 2,745 Net earnings attributable to noncontrolling interest3 3 6 6 Net earnings attributable to AbbVie Inc.$938 $1,370 $2,224 $2,739 Per share dataBasic earnings per share attributable to AbbVie Inc.$0.52 $0.77 $1.25 $1.54 Diluted earnings per share attributable to AbbVie Inc.$0.52 $0.77 $1.24 $1.53 Weighted-average basic shares outstanding1,768 1,768 1,768 1,769 Weighted-average diluted shares outstanding1,771 1,771 1,772 1,772 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 1

AbbVie Inc. and Subsidiaries Condensed Consolidated